Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2011-01-08035,2011,Jouquet                          2011 J Acquir Immune Defic Syndr,1000,Tenofovir (TDF) VERSUS Stavudine (d4T)-based regimens IN HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho,21765366,HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho,Tenofovir (TDF),Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.,Stavudine (d4T)-based regimens,NE
2011-01-08035,2011,Jouquet                          2011 J Acquir Immune Defic Syndr,Dominated,Zidovudine VERSUS Stavudine (d4T)-based regimens + Tenofovir (TDF) IN HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho,21765366,HIV-positive patients starting on antiretroviral therapy (ART) in Lesotho,Zidovudine,Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.,Stavudine (d4T)-based regimens + Tenofovir (TDF),NW
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
